Outcome of Board Meeting

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹649.20

prior close

₹668.95

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%+0.2% vs market

Hospital peers, median of 18sector+0.7%+0.4% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.4 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-2.1

15m

-2.2

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+0.8+0.2+0.7+0.4

Next day

-1.4+2.3-3.7+1.6-3.0

-0.9+3.0-3.9+2.5-3.5

-1.6+4.6-6.2+2.1-3.7

-1.0+5.3-6.3+1.3-2.3

-1.2+4.4-5.5+0.6-1.8

+2.7+4.8-2.1+1.5+1.2

15d

+4.0+8.2-4.2-1.1+5.0

+4.6+9.7-5.1+1.9+2.7

+9.7+13.5-3.9+9.7-0.0

+12.9+6.7+6.3+12.8+0.1

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 18Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

KIMS's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified opinion from S.R. Batliboi & Associates LLP. Consolidated revenue grew ~21.5% to Rs. 30,351 Mn (from Rs. 24,982 Mn) and consolidated profit after tax rose ~23.5% to Rs. 4,148 Mn (from Rs. 3,359 Mn). Standalone PAT grew ~28.5% to Rs. 3,029 Mn. The company completed the 100% acquisition of Chalasani Hospitals (Queen's NRI Hospital) for Rs. 1,112 Mn during the year and recognized a Rs. 108 Mn exceptional gain on call option valuation. The board also appointed IKR & Associates as Secretarial Auditors (5-year term), re-appointed Mrs. Y. Prameela Rani as Independent Director (5-year second term), and fixed the 23rd AGM for August 29, 2025.

Likely market impact

Strong consolidated revenue growth above 20% and healthy PAT growth signal robust operational performance and the Queen's NRI Hospital acquisition is already contributing. The clean audit report and no negative cash flow concerns are positive for shareholders; consolidated EPS rose to Rs. 9.61 (restated) from Rs. 7.75.